DLAT and renal cell carcinoma: In dead RCC patients, the genetic mutation frequency of CDKN2A was 3%, NFE2L2 and NLRP3 were 2%, and ATP7A, ATP7B, GLS, DLAT, DLD, LIAS, PDHA1, and PDHB were 1% (Figure 1D).